Kronos Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic treatments for cancer and other serious diseases. Their mission is to target dysregulated transcription that causes these conditions, aiming to bring forth groundbreaking therapies for patients in need. With a dedicated team, Kronos Bio values purposeful connections and is committed to making a meaningful impact.

Led by a team of experienced leaders, including President & CEO Norbert Bischofberger and Chief Medical Officer Jorge DiMartino, they have assembled an impressive Scientific Advisory Board, featuring notable experts in the field of cancer research. Kronos Bio's headquarters are located in San Mateo, California, while their research facility is in Cambridge, Massachusetts. They welcome partnering, media, investor, and employment inquiries, demonstrating their openness to collaboration and growth.

With a strong focus on innovation and improving patient outcomes, Kronos Bio is at the forefront of advancing cancer therapeutics